Moxetumomab Pasudotox-Tdfk for Hairy Cell Leukemia With Robert Kreitman, MD

Hairy cell leukemia (HCL) comprises only 2% of all leukemias and has limited treatment options. In a phase 3 trial, a team of researchers led by Robert Kreitman, MD, a medical oncologist at the National Cancer Institute, found that moxetumomab pasudotox-tdfk, a recombinant CD22-directed cytotoxin, achieved a high rate of durable response in patients with relapsed/refractory HCL. Dr. Kreitman presented the long-term follow-up results of the trial at the American Society of Hematology (ASH) Annual...
Continue reading

Adding Daratumumab to VMP for Transplant-Ineligible Myeloma: Maria Victoria Mateos, MD, PhD

Over half of patients with newly diagnosed multiple myeloma (NDMM) are ineligible for autologous stem cell transplantation. For these patients, a combination therapy consisting of the proteasome inhibitor bortezomib with melphalan and prednisone is one of the preferred treatments. Adding daratumumab to standard regimens for transplant-ineligible NDMM and relapsed/refractory multiple myeloma has had promising results. Now, data from the phase 3 ALCYONE trial show that adding daratumumab to bortez...
Continue reading

Acalabrutinib in Chronic Lymphocytic Leukemia: Jeff Sharman, MD

​In patients with previously untreated chronic lymphocytic leukemia (CLL), the interim results of the phase 3 ELEVATE-TN trial have revealed that acalabrutinib (Calquence®, AstraZeneca) improves progression-free survival, either as monotherapy or in combination with obinutuzumab (Gazyva®, Genentech). This study led to the recent FDA approval of acalabrutinib for CLL and small lymphocytic lymphoma (SLL). In this interview with i3 Health, Jeff P. Sharman, MD, the trial's principal investigator, di...
Continue reading

Osimertinib for EGFR-Mutated Advanced NSCLC: An Interview with Suresh S. Ramalingam, MD

The treatment of advanced-stage non-small cell lung cancer (NSCLC) has improved steadily in the past few years, and individualized therapy for patients with mutations in the epidermal growth factor receptor (EGFR) is applied in routine clinical practice. While EGFR-mutated NSCLC is effectively treated with tyrosine kinase inhibitors (TKIs) such as erlotinib or gefitinib, there is a need to develop more effective treatments to improve outcomes in these patients. In a study now published in The Ne...
Continue reading

Prescribing a Healthy Diet and Exercise for Breast Cancer With Neil Iyengar, MD

Patients with breast cancer can derive significant benefits from eating well and staying physically active during their treatment. In his previous interview with i3 Health, Neil Iyengar, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, explained the roles that nutrition and exercise can play in the prevention and treatment of breast cancer. In this second installment, Dr. Iyengar discusses the personalized strategies that are most likely to benefit patients. In addition, he of...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.